Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.
This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.
Some topics covered:
- The Pathophysiology of COVID-19
- Patient and Disease Features that Increase Risk of COVID-19 Infection and Complications in Patients with Lung Cancer
- Recommendations for Managing Patients with Lung Cancer in the COVID-19 Pandemic
Sandra Cuellar, PharmD, BCOP
University of Illinois at Chicago College of Pharmacy
Clinical Oncology Pharmacist, UI Health
J. Morgan Freiman, MD, MSc
Infectious Diseases Physician
Director of Antimicrobial Stewardship
Lahey Hospital and Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Antonio Passaro, MD, PhD
Division of Thoracic Oncology
European Institute of Oncology
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Beth Sandy, CRNP
View accreditation and register by clicking here.